Carmell Therapeutics Corporation (CTCX) Financial Analysis & Valuation | Quarter Chart
Carmell Therapeutics Corporation (CTCX)
CTCXPrice: $0.2
Fair Value: 🔒
🔒score
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, denta... more
Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM)... more
Description
Shares
| Market Cap | $5.94M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Rajiv Sarman Shukla |
| IPO Date | 2021-09-23 | CAGR | — |
| Employees | 9 | Website | www.carmellrx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CTCX chart loading...
Fundamentals
Technicals
| Enterprise Value | $-1.05M | P/E Ratio | 0.41 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 0.77 | P/B Ratio | -0.18 |
| P/CF Ratio | -0.18 | P/FCF Ratio | -0.22 |
| EPS | $0.48 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 8438.66% | Gross Margin | 0.57% |
| Operating Margin | -5.51% | Profit Margin | -6.83% |
| ROE | 1.76% | ROA | -1.93% |
| ROCE | 1.81% | Current Ratio | 0.47 |
| Quick Ratio | 0.3 | Cash Ratio | 0.22 |
| Debt/Equity | -0.1 | Interest Coverage | -261.02 |
| Altman Z Score | -34.05 | Piotroski Score | 3 |